Artwork

Innhold levert av The Connecticut Paid Leave Authority. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av The Connecticut Paid Leave Authority eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Living With Early Onset Alzheimer's Disease and Living Your Best Life.

33:40
 
Del
 

Manage episode 425439586 series 3314587
Innhold levert av The Connecticut Paid Leave Authority. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av The Connecticut Paid Leave Authority eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

This is an exciting time for anyone suffering from early onset Alzheimer's disease. A new drug that should get FDA approval by the end of this year, would expand the treatment options for the more than 6 million Americans of all ages who have Alzheimer's. The disease is the fifth-leading cause of death for adults over 65. Donanemab, a drug developed by Eli Lilly and Company, showed promising results in clinical trials. The drug eliminates brain plaques associated with Alzheimer's. Studies show the drug could be a breakthrough in treating early stages of the disease, slowing cognitive decline in those with early symptoms.
Joe Montminy is a patient advocate who is living with younger onset dementia and is currently serving on the MA/NH Alzheimer’s Association Board of Directors and the New England Alzheimer’s Association Early-Stage Advisory group. He used to live in CT and was diagnosed at 54 years old, it took 3 years before he could get a correct diagnosis. Joe says he is optimistic that this new drug and exciting new blood testing to get an earlier diagnosis, is going to make a big difference. Joe keeps a very positive attitude and finds comfort in a support group. Kristen Cusato is the Director of Communications for the Alzheimer's Association Connecticut Chapter & she is a New England Research champion. Kristen thinks that education is key and knowing the early signs of the disease, which can lead to an early diagnosis and treatment. She believes people like Joe can help with his advocacy, but more importantly he can bring hope with his story of struggle with early onset Alzheimer's disease.
To get in touch with the CT chapter of the Alzheimer's Association: Connecticut Chapter (alz.org)
To get information or to apply for benefits: CT Paid Leave

https://ctpaidleave.org/s/?language=en_US
https://www.facebook.com/CTPaidLeave

https://www.instagram.com/ctpaidleave/

https://twitter.com/CTPaidLeave
https://www.youtube.com/results?search_query=ct+paid+leave

  continue reading

59 episoder

Artwork
iconDel
 
Manage episode 425439586 series 3314587
Innhold levert av The Connecticut Paid Leave Authority. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av The Connecticut Paid Leave Authority eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

This is an exciting time for anyone suffering from early onset Alzheimer's disease. A new drug that should get FDA approval by the end of this year, would expand the treatment options for the more than 6 million Americans of all ages who have Alzheimer's. The disease is the fifth-leading cause of death for adults over 65. Donanemab, a drug developed by Eli Lilly and Company, showed promising results in clinical trials. The drug eliminates brain plaques associated with Alzheimer's. Studies show the drug could be a breakthrough in treating early stages of the disease, slowing cognitive decline in those with early symptoms.
Joe Montminy is a patient advocate who is living with younger onset dementia and is currently serving on the MA/NH Alzheimer’s Association Board of Directors and the New England Alzheimer’s Association Early-Stage Advisory group. He used to live in CT and was diagnosed at 54 years old, it took 3 years before he could get a correct diagnosis. Joe says he is optimistic that this new drug and exciting new blood testing to get an earlier diagnosis, is going to make a big difference. Joe keeps a very positive attitude and finds comfort in a support group. Kristen Cusato is the Director of Communications for the Alzheimer's Association Connecticut Chapter & she is a New England Research champion. Kristen thinks that education is key and knowing the early signs of the disease, which can lead to an early diagnosis and treatment. She believes people like Joe can help with his advocacy, but more importantly he can bring hope with his story of struggle with early onset Alzheimer's disease.
To get in touch with the CT chapter of the Alzheimer's Association: Connecticut Chapter (alz.org)
To get information or to apply for benefits: CT Paid Leave

https://ctpaidleave.org/s/?language=en_US
https://www.facebook.com/CTPaidLeave

https://www.instagram.com/ctpaidleave/

https://twitter.com/CTPaidLeave
https://www.youtube.com/results?search_query=ct+paid+leave

  continue reading

59 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett